Search the Newsreel

Odysight.ai Inc. Common Stock (NASDAQ: ODYS) Share Price, ODYS Stock News, ODYS Share Price & Updates

This page provides current stock information for Odysight.ai Inc. (NASDAQ: ODYS), including its real-time share price, daily range, and recent news. It also lists key financial fundamentals, upcoming events like conference participations, and links to financial reports such as quarterly and full-year results.

SGHT insider Jeremy Hayden files Form 144 for recent and planned stock sales

Jeremy Hayden, an insider at Sight Sciences, Inc. (SGHT), has filed a Form 144 detailing planned sales of common stock through Fidelity Brokerage Services LLC. The filing also reports prior restricted stock vestings from January 2024, March 2024, and a scheduled vesting in January …

Keysight Technologies Inc. stock outperforms competitors on strong trading day

Keysight Technologies Inc. (KEYS) shares rose 3.14% to $354.50 on Wednesday, outperforming the mixed market session. The S&P 500 Index saw a slight gain, while the Dow Jones Industrial Average experienced a small decline. This marks the second consecutive day of gains for Keysight …

Odysight.ai to Participate in Upcoming Investor Conferences

Odysight.ai Inc., a company specializing in AI-powered visual sensing and predictive maintenance, announced its participation in two upcoming investor conferences. CEO Yehu Ofer and CFO Einav Brenner will present at the Sidoti Virtual Micro-Cap Conference in August 2026, and CFO Einav Brenner will attend …

Odysight.ai CEO and CFO set for two Q3 presentations

Odysight.ai (NASDAQ/TASE: ODYS) announced that its CEO, Yehu Ofer, and CFO, Einav Brenner, will participate in two investor conferences in Q3 2026. They will present virtually at the Sidoti Virtual Micro-Cap Conference on August 20, 2026, and the CFO will also present at the …

Wedge Capital Management L L P NC Increases Stock Position in Keysight Technologies Inc. $KEYS

Wedge Capital Management L L P NC significantly increased its stake in Keysight Technologies Inc. (NYSE:KEYS) by 12% in the second quarter, bringing its total holdings to 230,131 shares valued at approximately $80.6 million. Keysight Technologies, a provider of electronic design and test solutions, …

G&S Capital LLC Takes $3.28 Million Position in Keysight Technologies Inc. $KEYS

G&S Capital LLC has acquired a new position in Keysight Technologies Inc. (NYSE:KEYS), purchasing 9,358 shares valued at approximately $3.28 million during the second quarter. Institutional investors now own 84.58% of the company, which recently reported strong quarterly earnings, beating estimates with $2.87 EPS …

Keysight Technologies Inc. $KEYS Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in Keysight Technologies Inc. by 3.6% in the second quarter, selling 3,756 shares and holding 99,283 shares valued at $34.76 million. Other institutional investors have also adjusted their holdings, and company insiders have recently sold shares. Keysight Technologies' …

Assenagon Asset Management S.A. Has $7.40 Million Holdings in Insight Enterprises, Inc. $NSIT

Assenagon Asset Management S.A. significantly increased its stake in Insight Enterprises, Inc. (NASDAQ:NSIT) by 34.6% in the second quarter, bringing its total holdings to $7.40 million. This move is part of a broader trend of institutional investors expanding their positions in Insight Enterprises, reflecting …

Insight Enterprises’s Q2 Earnings Call: Our Top 5 Analyst Questions

Insight Enterprises's Q2 Earnings Call: Our Top 5 Analyst Questions Insight Enterprises delivered results for Q2 that surpassed Wall Street's expectations, with management highlighting robust demand for infrastructure hardware and continued momentum in cloud and core services. CEO Jack Azagury cited over 20% growth …

Insight Digital Partners II (DYOR) Earnings Date and Reports 2026

Insight Digital Partners II (DYOR) reported its Q2 2026 earnings on August 11, 2026, with an EPS of $0.06. The company's stock closed at $10.10 on August 11, 2026. Investors can sign up for alerts to stay updated on future earnings announcements and reports.

Insight Molecular Diagnostics to Host Virtual KOL Event on

Insight Molecular Diagnostics Inc. (iMDx) will host a virtual KOL event on August 17, 2026, to discuss its GraftAssure platform and the potential for in-house heart transplant rejection testing. The event will feature Dr. Max Jacob Liebo, alongside iMDx's VP of Medical Affairs and …

Doctors to discuss in-house heart transplant testing Aug. 17

Insight Molecular Diagnostics (Nasdaq: IMDX) will host a virtual Key Opinion Leader (KOL) event on August 17, 2026, to discuss its GraftAssure dd-cfDNA platform. The event will feature cardiologist Max Jacob Liebo, MD, and iMDx executives, focusing on the GraftAssureDx kit for kidney and …

Sight Sciences Inc (NASDAQ: SGHT) Share Price, SGHT Stock News, SGHT Share Price & Updates

SGHT (NASDAQ: SGHT) insider Jeremy Hayden plans $165,878 stock sale

SGHT insider Jeremy Hayden plans to sell 20,918 shares of common stock, valued at approximately $165,878.62, through Fidelity Brokerage Services on August 11, 2026. This sale relates to previously scheduled restricted stock vesting events. Hayden also reported a prior sale of 12,733 shares for …

Keysight Technologies Inc (KEYS) Stock Analysis & Forecast

This article provides an analysis and forecast for Keysight Technologies Inc (KEYS) stock, highlighting its role in the AI infrastructure sector. It emphasizes that AI infrastructure goes beyond GPUs, relying heavily on fast networks, reliable interconnects, and thorough testing, areas where Keysight's validation and …

Insight Digital Partners II Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Insight Digital Partners (DYOR) earns $2.7M but flags going concern risk

Insight Digital Partners II Q2 2026: Net income $1.4M, EPS $0.06— 10-Q Summary

Insight Digital Partners II reported net income of $1.4 million for Q2 2026, with diluted earnings per share of $0.06. For the first six months of 2026, consolidated net income was $2.66 million and diluted EPS was $0.12. The company's business focus is on …

California State Teachers Retirement System Grows Holdings in Insight Enterprises, Inc. $NSIT

The California State Teachers Retirement System significantly increased its stake in Insight Enterprises (

IMDX Looks 284.7% Overvalued on GF Value™

Insight Molecular Diagnostics Inc (IMDX) is considered 284.7% overvalued based on its GF Value™ despite optimism around future FDA authorization for its GraftAssureDx test and expanded Medicare reimbursement. The company reported a Q2 adjusted EBITDA loss and an upward revision of its cash burn …

Insight Molecular Diagnostics signals ~$8M quarterly cash burn in H2 2026 while targeting FDA authorization later this year

Earnings Call Insights: Insight Molecular Diagnostics (IMDX) Q2 2026 MANAGEMENT VIEW * "It feels great to be coming to you today with line of sight on expected FDA marketing authorization for GraftAssureDx" (President, CEO & Director Joshua Riggs), adding, "We continue to target receipt …

Price to earnings forward of Foresight Environmental Infrastructure Limited GBP – LSE:FGEN

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down By Investing.com

Sight Sciences (NASDAQ:SGHT) has announced the appointment of Kashif Rashid as its new chief legal officer and corporate secretary, effective Monday. Rashid brings extensive legal leadership experience from previous roles at Nevro Corp. and other companies. Concurrently, Jeremy Hayden will step down from the …

Sight Sciences appoints Kashif Rashid as chief legal officer, Jeremy Hayden to step down

Sight Sciences, Inc. has announced the appointment of Kashif Rashid as its new chief legal officer and corporate secretary, effective immediately. Rashid brings extensive experience from previous legal leadership roles at several companies, and his compensation package includes an annual base salary of $450,000, …

Earnings call transcript: Insight Molecular Diagnostics posts mixed Q2 2026 results

* Insight Molecular Diagnostics Inc. (IMDX [https://seekingalpha.com/symbol/IMDX]) is scheduled to announce Q2 earnings results on Monday, August 10th, after market close. * The consensus EPS estimate is -$0.25, [https://seekingalpha.com/symbol/IMDX/earnings/estimates] and the consensus revenue estimate is $0.44M * Over the last year, IMDX has beaten …

Insight Molecular Diagnostics earnings beat, revenue fell short of estimates

Insight Molecular Diagnostics (NASDAQ: IMDX) reported second-quarter EPS of $-0.230, exceeding analyst estimates of $-0.240. However, the company's revenue of $240K fell short of the consensus estimate of $470.85K. Despite the revenue miss, the company's stock price has shown significant volatility, being down -25.700% …

Insight Molecular Diagnostics: Q2 Earnings Snapshot

The provided content is not an article but rather a privacy notice or a placeholder. It does not contain any information about Insight Molecular Diagnostics or its Q2 earnings. Therefore, no meaningful summary can be generated.

Form 8K Sight Sciences Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Sight Sciences Inc. for August 10, 2026. It is a brief, standard financial news update provided by Investing.com, indicating a regulatory filing has occurred for the company.

Stifel Nicolaus Lowers RxSight (NASDAQ:RXST) Price Target to $7.00

Stifel Nicolaus has reduced its price target for RxSight (NASDAQ:RXST) from $8.00 to $7.00, while maintaining a "hold" rating, suggesting an 11.82% potential upside. Despite the lowered target, RxSight recently reported better-than-expected quarterly results, surpassing analyst estimates for both earnings per share and revenue. …

Form 8K Insight Molecular Diagnostics Inc For: 10 August By Investing.com

This article announces the filing of a Form 8K by Insight Molecular Diagnostics Inc. on August 10. The filing is a standard regulatory announcement, and the article provides no further details beyond the company name and filing date. It appears to be a placeholder …

Insight Molecular Diagnostics (Nasdaq: IMDX) reports steep revenue drop but bolsters cash

Insight Molecular Diagnostics (IMDX) reported a steep revenue drop in Q2 2026, with net revenue down sharply to $239,000 from $518,000 in the prior year, and a net loss of $11.3 million. Despite the revenue decline and increased operating expenses, the company bolstered its …

IMDX Reports Second Quarter 2026 Results and Timely Progress on FDA Review of GraftAssureDx

Insight Molecular Diagnostics Inc. (IMDX) reported its Q2 2026 results and provided an update on the FDA review of its GraftAssureDx product. The company is progressing with the FDA, expecting marketing authorization soon, and highlighted favorable Medicare reimbursement policy changes. IMDX also shared clinical …

Keysight Technologies Inc. stock underperforms Monday when compared to competitors

Keysight Technologies Inc. (KEYS) shares dropped 1.63% on Monday, closing at $335.41. This underperformance occurred on a generally down day for the stock market, with both the S&P 500 and Dow Jones Industrial Average also seeing slight declines. The stock's fall ended a two-day …

Can Rising Power Analyzer Demand Reshape Keysight Technologies’ (KEYS) Role in the Electrification Ecosystem?

Insight Enterprises (NASDAQ:NSIT) Reaches New 1-Year High After Analyst Upgrade

Insight Enterprises (NASDAQ:NSIT) reached a new 52-week high after JPMorgan Chase & Co. raised its price target from $135 to $160, maintaining a neutral rating. The company reported strong quarterly earnings of $3.86 EPS on $2.40 billion in revenue, exceeding analyst estimates. Despite the …